BioSpace News Archive

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presented at the 63rd American Society of Hematology Annual Meeting being held virtually and in Atlanta, GA December 11-14, 2021.

Shasqi announced upcoming presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, taking place virtually and in person in Washington, DC, on November 10–14, 2021, and at the Connective Tissue Oncology Society’s Annual Meeting, being held virtually on November 10–13, 2021.

bluebird bio, Inc. announced that new data from its lentiviral vector gene addition programs for patients with β-thalassemia who require regular red blood cell transfusions and sickle cell disease will be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, taking place December 11-14, 2021, at the Georgia World Congress Center in Atlanta, Georgia, and virtually.

Ambu Inc., the world leader in single-use endoscopy, announced that an Ohio gastroenterologist has become the first physician in the U.S. to use Ambu’s new sterile, single-use duodenoscope in 100 endoscopic retrograde cholangiopancreatography procedures.

Beyond Air, Inc. today announced the separation of its oncology business into a new and independently managed, private company called Beyond Cancer, Ltd.

Sol-Gel Technologies, Ltd. today announced a new agreement with Padagis (formerly a division of Perrigo Company plc) (the “Agreement”), which will replace prior collaborative agreements for the development and commercialization of certain generic drugs for skin diseases.

Alterity Therapeutics today announced the publication of two preclinical studies demonstrating the potential of ATH434 to treat Parkinsonian disorders.

Biohaven Pharmaceutical Holding Company Ltd. will hold its upcoming third quarter 2021 earnings call and webcast, reporting financial results for the quarter ended September 30, 2021.

Mind Cure Health Inc. is pleased to provide an operational progress update on the strategic initiatives of its operating segments

XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 development stage, triggering a $35 million milestone payment from Novartis.